Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - salmeterolum xínafóat - innúðalyf, dreifa - 25 míkróg/skammt

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - salmeterolum xínafóat - innöndunarduft - 50 míkróg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz gmbh* - rifampicinum inn - hart hylki - 300 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz gmbh* - rifampicinum inn - hart hylki - 150 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - lyf til veikindi öndunarvegi sjúkdómum, - ofnæmi asthmaxolair er ætlað í fullorðnir, unglingum og börn (6.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - lyf til veikindi öndunarvegi sjúkdómum, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva sweden ab - montelukastum natríum - filmuhúðuð tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva sweden ab - montelukastum natríum - tuggutafla - 4 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva sweden ab - montelukastum natríum - tuggutafla - 5 mg